Фармакокинетика левофлоксацина как основа режима дозирования и оптимизации схем лечения
Аннотация
Описана клиническая фармакокинетика левофлоксацина.
Список литературы
1. Haykava I., Atarachi S., Yokohama S. et al. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother 1986; 29: 163-164.
2. Uno T., Fujimoto T., Sato K. et al. In vitro activity of DL-3355, an optically active ofloxacin. Ibid; 1988; 1336-1340.
3. Fu K.P., Lafredo S.C., Foleno B. et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Ibid; 1992; 36: 860-866.
4. Tavanic (levofloxacin) iv/oral. Scientific Product Monograph. Hoechst-Merion-Russel, 1999.
5. Mollering B.C. Overview of newer quinolones. Levofloxacin. Symp 19th Intern Congr Chemother, Montreal, 1995; 45-58.
6. The Quinolones, 2nd ed., Eds. Andriole V.T., Academic Press, London, New York, 1998; 441.
7. Quinolone Antimicrobial Agents. 2nd ed., Eds. Hooper D.C., Wolfson J.S. Washington, 1993; 549.
8. Paladino J.A. Is more than one quinolone needed in clinical practice? Ann Pharmacother 2001; 35: 1085-1095.
9. Zhanel G.C., Ennis K., Vercagne L. et al. A critical review of quinolones. Focus on respiratory tract infectious. Drugs 2002; 62: 1: 13-59.
10. Падейская Е.Н., Яковлев В.П. Антимикробные препараты группы фторхинолонов в клинической практике. «Логата», М.: 1998; 351.
11. Яковлев В.П., Литовченко К.В. Левофлоксацин – новый антимикробный препарат группы фторхинолонов. Инфекции и антимикробная терапия 2001; 3: 5: 132-140.
12. Падейская Е.Н. Левофлоксацин (Таваник®) – новый препарат группы фторхинолонов для лечения инфекционных заболеваний с широкими показаниями к применению. Качественная клиническая практика 2002; 2: 80-94.
13. Яковлев В.П., Яковлев С.В. Изучение левофлоксацина в России. Инфекции и антимикробная терапия 2004; 6: 4: 108-114.
14. Hepburn M.J., Dooley D.P., Skidmore P.J. et al.Comparison of short-course (5 days) and standart (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164: 15: 1669-1674.
15. File T.M., Milkovich G., Tennenberg A.M. et al. Clinical implications of 750 mg, 5-days levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin 2004; 20: 9:1473-1481.
16. Norredin A.M., Marras T.K., Sanders K. et al. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg, and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents 2004; 24: 5: 479-484.
17. File T.M. New insights in the treatment by levofloxacin. Chemotherapy 2004; 50: Suppl.1: 22-28.
18. “Levaquin” levofloxacin. Product Monograph, Janssen-Ortho Inc 2005; 59.
19. Падейская Е.Н. Основные итоги исследований в ряду антимикробных препаратов класса хинолонов к началу ХХ1 века: успехи и неудачи в разработке новых высокоэффективных фторхинолонов. Антибиотики и химиотерапия 2001; 46: 8: 32-39.
20. Petermann W., Barth J. Once-a-Day Ofloxacin in pneumonia. Proc. 17-th Intern Congr Chemother, Berlin, 1991; 310-311.
21. Giamarellou H. The use of Ofloxacin in the chronic ambulatory patients: the benefits of once-daily therapy. Penetration, Intern. Update on Ofloxacin. Annual Issue, 1995; 5-10.
22. Davis B.I. Once-daily Ofloxacin in respiratory tract infections. Ibid.; 17- 21.
23. Lehr K.H., Damm P. Quantification of the enantiomers of ofloxacin in biological fluids by HPLC. J Chromatogr 1988; 425: 153.
24. Chien S.C., Chow A.T., Natarajan J. et al. Absence of age and gender effects on the pharmacokinetics of a single 500 mg dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997; 41: 1562-1565.
25. Chien S.C., Rogge M.C., Gisclou L. et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Ibid; 2256-2260..
26. Chien S.C., Wrong F.A., Flower C.L. et al. Double-blind evaluation of safety and pharmacokinetics of multiple oral once-daily 750-mg and 1-gram doses of levofloxacin in healthy volunteers. Ibid, 1998; 42: 885-888..
27. Fish D.N., Chow A.W. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101-119.
28. Davis B., Bryson H.M. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs; 1994; 47: 677-700.
29. Aminimanizani A., Berlinger P., Jelliffe R.comperative pharmacokinetics and pharmacodynamics of newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001; 40: 3: 169-187.
30. Keller I., Lubasch A., Rau M. et al. Comparative pharmacokinetic of ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin after a single oral administration in healthy volunteers. 39th Inter.Conf Antimicrob Agents Chemother, San Francisco, 1999; Abstracs: N 30.
31. Holland M., Chien S., Corrado M. et al. The phamacokinetic profile of intravenous levofloxacin following once- or twice-daily administration. 5th Intern Symp New Quinolones, Singapore, 1994; [poster].
32. Turinge J. Pharmacokinetic and pharmacodynamic of fluoroquinolones. Drugs; 1999; 58: Suppl 20: 29-36.
33. Lubash A., Keller I., Borner K. et al. Comparative pharmacokinetica of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administrationin healthy volunteers. Antimicrob Agents Chemother 2000; 44: 10: 2600-2603.
34. Ohi Y., Goto T., Kawahara K. et al. Penetration of fluoroquinolones into human spinal fluid. Chemotherapy 1992; 40: 469-473.
35. Nagai H., Yamasaki T., Masuda M. et al. Penetration of levofloxacin into bronchoalveol lavage fluid. Drugs 1993; 45: Suppl. 3: 259.
36. Nakamori Y., Tsudoi E., Narui K. et al. Sputum penetration of levofloxacin and its clinical efficacy in patients witn chronic lower respiratory tract infections. Jap. J Antibiot 1992; 45: 539-547.
37. Yamashida M., Sawada K., Chokyu H. et al. Prostatic tissue levels of levofloxacin. Chemotherapy 1992; 40: 203-209.
38. Takahashi H., Mogi S., Kobayashi M. et al. Assay of skin level and clinical investigation of levofloxacin in the treatment of skin infections. Ibid; 286-305.
39. Child J., Mortiboy D., Andrews J.M et al. Open-lebel crossover study to determine pharmacokinetics and penetration of too dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother 1995; 39: 12: 2749-2751.
40. Garcia I., Pascual A., Ballesta S. et al. Uptake and intracellular activity of ofloxacin and its isomers levofloxacin and D-ofloxacin in himan phacocytic and non-phagocytic cells. 8th Eur Congr Clun Microbiol Infec Dis, Losanne, 1997; Abstracts: N P376.
41. Honeybourne D., Andrews J. M., Jevons G. et al. Penetration of levofloxacin (HR355) into lung tissues after a singl 500 mg oral dose. Ibid; N P377.
42. Reports from the 10th European Congress of Clinical Microbiological and Infectious Diseases, Stockholm, Sweden, 2000: Highlights of Symposia 1. Penetration, International Update on Levofloxacin and Ofloxacin, 2001: 48-55.
43. Rimmele T., Boselli E., Breilh D. et al. Diffusion of levofloxacin into bone and synovial tissues. J Antimicrob Chemother 2004; 53: 3: 533-535.
44. Яковлев В.П., Блатун Л.А., Митиш В.А. и др. Ступенчатое применение левофлоксацина при лечении больных с раневой инфекцией. Инфекции и антимикробная терапия 2004;6: 1: 21-24.
45. Boselli E., Breilh D., Rimmele T et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med 2005;33: 1: 104-109.
46. Liapakis I.E., Kottakis I., Tzatzarakis M.N. et al. Penetration of newer quinolones in the empyema fluid. Eur Respir J 2004; 24: 3: 466-470.
47. Oberdorfer K., Swoboda S., Hamann A. et al. Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J Antimicrob Chemother 2004; 54: 4: 836-839.
48. Limaye A.P., Hooper C.J. Treatment of tularemia with fluoroquinolones: two cases and rewiew. Clin Inf Dis 1999; 29: 922-924.
49. Cunha B.A. Anthrax, tularemia, plague, ebola or smallpox as agents of bioterrorism: recognition in the emergency room. Clin Microbiol Infect 2002; 8: 489-503.
50. Frean J.A., Arntzen L., Capper T et al. In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from Southern African plage focus. Antimicrob Agents Chemother 1996;40: 2646-2647.
51. Ikaheimo I., Syrjala H., Kahukorpi J. et al. In vitro susceptibility of Francisella tularensis isolated from humans and animals. J Asntimicrob Chemother 2000; 46: 287-290.
52. Trojillano-Marin I., Garcia-Sanches E., Martinez I.M. et al. In vitro activities of six new fluoriquinolones against Brucella melitensis. Antimicrob Agents Chemother 1999; 43: 194-195.
53. Memish Z.A., Mah M.W. Less usual indications: Mycobacteria, Brucella, Yersinia, Francisella and other infections. Fluoroquinolone Antubiotics, Eds. Ronald A.R., Low D.E., Birkhauser Velag| Swtzerland, 2003; 239-249.
54. DrusanoG.L., Preston S.L., Flower C. et al. Relationship between fluoriquinolone area under the curve. Minimum imhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumoniae. J Infect Dis 2004; 189: 9: 1590-1597.
55. Dunbar L.M., Wunderink R.G., Habib M.P. et al. High-dose, short-cours levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infec Dis 2003; 37: 752-760.
56. West M., Boulanger B.R., Forgarty C. et al. Levofloxacin compared with imipenem/ cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, ohen-label study. ClinTher 2003; 25: 2: 485-505.
57. Nightingale C.H., Grant E.M., Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chtmotherapy 2000; 46: Suppl.1: 6-14.
58. Geerdes-Fenge H.F., Wiedersish A., Wagner S. et al. Levofloxacin pharmacokinetics and serum bactericidal activities against five Enterobacterial species. Antimicrob Agents Chemother 2000;44: 12: 3478-3480.
59. Malone R.S., Fish D.N., Abraham E., Teitelbaum I. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically III patients. Ibid, 2001; 45: 10:2949-2954.
60. Firsov A.A., Zinner S.H., Vostrov S. et al. AUC/MIC relationships to different endpoint of the antimicrobial effwect: multipl-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother 2002; 50: 533-539.
61. Lubenko I.Y., Vostrov S.N., Portnoy Y.A. et al. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflectiong comparative fluoroquinolone antipseudomonal pharmacodynamics in an in vitro dynamic model. Int J Antimicrob Agents 2002; 20: 44-49.
62. Drusano G.L., Moore K.H., Klim J.P. et al. Rational dose selection for non-nucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modelig and Monte Carlo simulation. Antimicrob Agents Chemother 2002; 46: 913-916.
63. Forrest A., Ballow C.H., Nix D.E. et al. Development of population pharmacokinetic model and optimum sampling strategies for intravenous ciprofloxacin. Ibid 1993; 37: 1065-1072.
64. Wallis R.S, Palaci M., Vinhap S. et al. A whole blood bactericidal assay for tuberculosis. J Infect Dis 2001; 183: 1300-1303.
65. Drancourt M., Gallais H., Racult D et al. Ofloxacin penetration into cerbrospinal fluid. J Antimicrob Chemother 1988; 22: 263-265.
66. Todd P.A., Faulds D. Ofloxacin. A reapprisal of its antimicrobial actibvity, pharmacology and therapeutis use. Drugs 1991; 42: 825-876.
67. Nau R., Kinzig M., Dreyhaupt T. et al. Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin. Antimicrob Agents Chother 1994; 38: 1849-1853.
68. Pioget J., Wolff M., Singlas E. et al. Diffusion of ofloxacin into cerebrospinal fluid of patients with purulent meningitis or ventriculitis. Antimicrob Agents Chemother 1089; 33: 933-936.
69. Debache C.J., Pakiz C.B., Larsen C. et al. Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in experimantal rabbit meningitis model. J Antiomicrob Chemother 2001; 47:611-615.
70. Scotton P.G., Pea F., Giobbia M, et al. Cerebrospinal fluid penetrattion of levofloxacin in patients with spontaneus acute bacterial meningitis. Clin Infect Dis 2001; 33: E109-E111.
71. Pea F., Scotton P.G., Giobbia M. et al. Cerebrospinal fluid penetration of levofloxacin duting cotreatment for bacterial meningitis. J Antimicrob Chemother 2001; 47: Suppl. 1.
72. Pea F., Pavan F., Nascimben E. et al. Levofloxacin dispositiion in cerebrospinal fluid in patients with external ventriculostomy. Antimicrob Agents Chemother 2003: 47: 10: 3104- 3108
73. Saito A., Oguchi K., Harada Y. Pharmacokinetics of levofloxacin in patients with impaired renal function. Chemotherapy 1992; 40: Suppl 3: 188-195.
74. Gisclon L.G., Curtin C.R., Chien S.C. et al. 36th Intersc Conf Antimicrob Agents Chemother 1996; Abstracts: N A13.
75. Яковлев В.П., Яковлев С.В. Возможности профилактического и лечебного применения левофлоксацина. Таваник (левофлоксацин). Научное досье. «Авентис Интерконтиненталь», 4-17.
76. Соколова Г.Б. Левофлоксацин (Таваник) в комплексной терапии туберкулеза. Информационное письмо для врачей-фтизиатров, Москва, 2004; 1-8.
77. Sprandel K.A., Schrever C.A., Pendland S.L. et al. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and verious doses of metronidazole in healthy adult subjects. Antimicrob Agents Chemother 2004; 48: 12: 4597-4605.
78. Падейская Е.Н. Фторхинолоны в педиатрии. Состояние проблемы к началу ХХI века. Антибиотики и химиотерапия, 2004; 49: 7: 34-44.
79. Волков И.К., Катосова Л.К., Давыдова И.В. и др. Эффективность левофлоксацина (Таваник) при хронических заболеваниях легких у детей. Там же, 17-21.
Рецензия
Для цитирования:
Падейская Е.Н. Фармакокинетика левофлоксацина как основа режима дозирования и оптимизации схем лечения. Клиническая фармакокинетика. 2005;(2):58-71.
Просмотров: 428
Послать статью по эл. почте 